Investigation of Efficacy and Safety of Botulinum Toxin A (Botox-Allergan Inc) in Migraine Headaches
What is the purpose of this trial?
The hypothesis of this study is that injection of botulinum toxin A into the muscles around the head (frontal, temporal, posterior neck, occipital) can reduce the intensity and frequency of migraine headaches by 50% and more and this effect is even more positive after second treatment.
Dates: January 2008 - December 2009
Study Status: Recruiting
Who can participate?
Ages Eligible: 18 Years and older
Gender Eligible: Both
Inclusion Criteria
- Adults 18 and older
- Anti-migraine drug, meeting criteria of chronic migraine
Exclusion Criteria
- Age below 18
- Pregnant or may become pregnant
- Disease of neuromuscular junction or drugs that affect N-M junction
- Allergy to Botox
- Previous use of Botox for migraine by similar methodology
Sponsor: Yale University
Phase: Phase 3
Clinicaltrials.gov ID: NCT00660192
Study HIC # 0709003056
For more information about this trial, contact
Diana Richardson, M.D.
(203) 737-1831
diana.richardson@yale.edu
Yale Researcher
Jabbari, Bahman
Principal Investigator
